What we think about Coherus BioSciences (CHRS)

Coherus in Three Words: Undervalued Niche Biotech

Discuss Coherus in our Community Forum

Background

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer. It recently commercialized Loqtorzi as a treatment for metastatic nasopharyngeal carcinoma and its pipeline is focused on developing other immunotherapies for cancer.

In December 2024, Coherus sold its Udenyca franchise to Intas Pharmaceutics for $558 million; which was a combination of $483 million upfront and $75 million from future milestones.

In June 2024, it sold its HUMIRA biosimilar drug Yusimry to Hong Kong King-Friend Industrial (HKF) for $40 million upfront.

Conviction Rating Changes

Coherus was downgraded from Buy to Potential Sell on March 11, 2025.

Join 7investing to get access to this section

Partner Promotions:

Recent Coherus BioSciences (CHRS) Recommendations

Members Only Content

Subscribe to get full access